Drug repositioning and molecularly targeted novel drug development are two contrasting strategies in cancer research. Yet, certain combinations of the two may bring together the best of both worlds. Drug repositioning, i.e. the use of a drug for treating diseases other than the drug-specified, is a strategy to advance patient care more quickly and efficiently. The idea was promoted in 2012 thro...

Objective: Erdheim-Chester disease is a rare form of non-Langerhans cell histiocytosis unknown etiology. It multisystemic that can involve bones, skin, brain, retroperitoneum, cardiovascular system, endocrine and lungs. Diagnosis made by clinical findings, imaging results, histopathological examination. BRAFV600E (B-rapidly accelerated fibrosarcoma gene) mutation found in more than half the cas...

Papillary thyroid cancer (PTC) is usually treated successfully with surgery and radioactive iodine therapy (RAI), but in some RAI-refractory patients metastatic symptomatic disease, systemic could be considered. BRAF mutations are detected over 80% of PTC Korea. Dabrafenib plus trametinib showed promising efficacy melanoma or non-small cell lung BRAFV600E mutation. This study evaluated the safe...